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Reducing Cardiovascular Disease
Opportunities and consequences
O
ne of the enduring myths in health
careisthatpreventionsavesmoney.
The intuition behind the idea ap-
pears unassailable: if we spend a little
money on preventive measures, we can
avoid the expensive complications of dis-
ease. The maxim “an ounce of prevention
is worth a pound of cure,” coined by Ben-
jamin Franklin and listed in the Dictio-
nary of Cultural Literacy (1), seems self-
evident such that it does not warrant
serious challenge. The “prevention saves
money” argument is popular with many
politicians and health policy makers. For
example, the recent Presidential primary
seasonwitnessedpledgesfrommanycan-
didates not only to improve health care
but also to save money by spending more
on prevention (2).
Careful analysis has shown that while
preventive care sometimes saves the health
system money, usually it does not (3). Eco-
nomic evaluations tend to conclude that al-
though preventing the need for treatment
canoffsetsomecostsfromavoidableillness,
the overall costs can be substantial because
ofthenumberofpeoplewhomustundergo
preventivemeasures(2).Moreover,preven-
tion does not avert death; it only postpones
it.Aspeopleage,theirhealthcostsincrease.
Therefore, activities and programs that
achievesavingsbypreventingafataldisease
can lead to downstream health care costs as
the people who would otherwise die grow
older.
Of course, this result does not mean
that as a society we should not invest in
prevention but, instead, that we should
do so with careful analysis and without
unrealistic expectations. Preventive mea-
surescostingmorethantheysavecanstill
represent good value for money, but
whether they will depends entirely on the
intervention and population at hand. The
studybyKahnetal.isawelcomeaddition
to this discussion (4). Their analysis,
which examined the effects of 11 nation-
ally recommended prevention activities
for cardiovascular disease (CVD)-related
morbidity, mortality, and costs in the
U.S., is important on several levels.
First, it quantiﬁes the enormous po-
tential health gains from preventing CVD
morbidity and mortality. Ensuring that
individuals receive appropriate preventa-
tive measures would, at feasible levels of
implementation, substantially reduce the
number of myocardial infarctions and
strokes, adding as many as 130 million
life-years and nearly 150 million quality-
adjusted life-years to the U.S. adult
population over a 30-year period. Aggre-
gatingoverthepopulation,thebiggestre-
ductions in life-years lost would come
from controlling blood pressure in the
nondiabetic population (140/90
mmHg), controlling blood pressure in
people with diabetes (130/80 mmHg),
and controlling pre-diabetes (fasting
plasmaglucose110mg/dl).Controlling
LDL cholesterol levels (100 mg/dl) in
coronary artery disease patients achieves
the largest improvement in individual life
expectancy, but the population impact is
limited by the fact that only 1.5% of all
individuals fall into this category.
Second, the authors arrive at a con-
clusion consistent with previous studies
but that will nonetheless come as a sur-
prise to many readers. Despite the health
gains, only one of the 11 evaluated pre-
ventative activities (smoking cessation) is
projected to save money. Although 100%
implementation of all 11 measures re-
viewed would decrease the $9.5 trillion
cost of caring for CVD, diabetes, and con-
gestiveheartfailureoverthenext30years
by approximately $900 billion, the pre-
vention activities themselves would cost
$8.5trillion,thusincreasingtotalmedical
costs by some $7.6 trillion.
Third, the paper shows the value of
formal cost-effectiveness analysis to help
guide priority setting and adds to the
ever-growing number of cost-utility stud-
ies in the literature (5). This kind of for-
mal analysis provides decision makers
with a structured, rational approach for
considering competing alternatives for
improving the return on resources ex-
pended. Kahn et al. show that smoking
cessation, aspirin, and control of pre-
diabeteslikelyrepresentthemostefﬁcient
waytoreduceCVD-relatedmorbidityand
mortality.
Fourth,thepaperillustratestheuseof
sophisticated computer-simulation mod-
els to help inform policy decisions. The
Archimedes model used by Kahn et al.
draws on detailed information on U.S.-
population disease patterns and health
care utilization to analyze downstream
clinical events and costs. As the authors
note, this kind of model is particularly
useful for research on preventative activ-
ities, where randomized controlled trials
are often unavailable and would be pro-
hibitively costly to conduct. Models do
not replace randomized controlled trials
but can extend them and enhance our
knowledge by simulating clinical trials
and asking “what if” questions: How
much morbidity, mortality, and cost are
potentially preventable? How do various
prevention activities compare in terms of
their cost-effectiveness?
A common objection to the issue of
simulation models is that their estimates
come at the cost of introducing uncertain
assumptions (6). However, the method-
ology does not introduce the uncertainty
associated with these assumptions.
Rather,itmakestheassumptionscontrib-
uting to this uncertainty explicit and
quantiﬁes the uncertainty’s impact on the
estimatedresults.Forexample,byrepeat-
ing their analysis using different sets of
plausible parameters, Kahn et al. deter-
mined that assumptions about the cost of
thepreventivemeasuresandtheproportion
of eligible individuals receiving services
contribute the most to the ﬁnal result’s un-
certainty.Tobesure,theprogrammingand
mathematics underlying the Archimedes
model are somewhat complex, but the al-
ternativetoformalmodelingistomakepol-
icy based on implicit assumptions about
future consequences.
Finally,thestudyunderscoresthefact
that the issue in prevention is largely not
one with insufﬁcient evidence regarding
which clinical prevention activities work.
Though there are undoubtedly opportu-
nities to improve this evidence base, the
activities analyzed by Kahn et al., as the
authors highlight, are supported by good
evidence and are widely accepted. In-
stead,theproblemishowtoincreasetheir
use in an efﬁcient manner. Part of the an-
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itiesandeducationandoutreacheffortsto
deliver services and improve compliance.
These activities cost money but may well
be worth the needed resources. We must
improve the evidence base on the cost-
effectiveness of such efforts. Part of the
answer also lies in systemic changes, such
as infrastructure to link clinicians with
community resources, and changes in the
systemtocreateincentivesthatencourage
the appropriate delivery of efﬁcient inter-
ventions (7).
Inanidealworld,criticalhealthcare–
spendingdecisionswouldbeinformedby
directly applicable randomized clinical
trial results. Because logistical and ethical
constraints make such evidence unavail-
able in many cases, information must be
synthesized and extrapolated across time
and to populations not directly studied.
As the analysis by Kahn et al. demon-
strates, the results are not always consis-
tent with intuition; in this case, it turns
out that prevention generally does not
save money. The analysis does, however,
identify interventions that efﬁciently pro-
duce health improvements and, hence,
suggests programs that policy makers
shouldtargettoincreasepopulationcom-
pliance. Given the substantial health im-
plications and health care resources
involved, using tools like the Archimedes
modelcanhelpensurethatwearemaking
the best use of available information to
identify measures to improve public
health.
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